Therefore, the challenge for IL12 and IFNγ immunotherapies for the treatment of cancer is to be able to trigger a strong recruitment and activation of anti-cancer adaptive immunity within the TME while minimizing the toxicity. This evidence concerns the gene IFNG and cancer.